

In all studies the clinical application of Arthrosamid® is safe and effective¹



CLINICAL STUDIES	Numbers of participants	Number of AE device related	Sensation of distension	Pain from target knee	Reduced range of motion	Joint swelling	Other
DAISY							
104 weeks ^{2,7}	91	41	15	7	4	-	15
IDA							
26 weeks ^{1,2}	49	14	-	7	-	3	4
52 weeks ^{2,8}	49	+2	-	+0	-	+0	+0
104 weeks ^{2,4}	35	+0	-	+0	-	+0	+0
156 weeks ⁹	35	+0	-	+0	-	+0	+0
ROSA							
52 weeks ^{2,5}	121	41	-	21	-	13	7

No intra-articular infections or allergic reactions were reported in this retrospective study⁷

No patients had severe adverse events linked to Arthrosamid®¹

1. Bliddal, H., et al. (2021) Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: A 6 Months Prospective Study. *J. Orthop. Res.* 6(2). 1188. ISSN 2575-8241; 2. Data on file; 3. Arthrosamid®, Instructions For Use, Release Date March 2022 10082-003; 4. Bliddal, H., et al. (2022) A Prospective Study of Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: Results From 2 Years After Treatment. Poster presented at OARSI 2022; 5. Bliddal, H., et al. (2022). One-year performance of polyacrylamide hydrogel vs. hyaluronic acid: A randomised controlled study. Poster presented at OARSI 2022; 6. Bliddal, H., et al. (2022). One-year performance of polyacrylamide hydrogel vs. hyaluronic acid in age, BMI, and Kellgren-Lawrence subgroups: A subgroup analysis of a randomised study. Poster presented at OARSI 2022. *Osteoarthritis and Cartilage* Vol.30, Supplement 1, S373-S374. DOI:10.1016/j.joca.2022.02.502; 7. Overgaard, A., et al. (2019) Safety of intra-articular polyacrylamide hydrogel for the treatment of knee osteoarthritis symptoms: A retrospective case series. *Clin Ortho Adv Res.* 6(2). 1188. ISSN 2575-8241; 8. Bliddal, H., et al. (2021) Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: Results of a 52 Week Prospective Study. *Osteoarthritis and Cartilage*. Vol.29 S278; 9. Henriksen, M., et al. (2023). 3 Year Results From a Prospective Study of Polyacrylamide Hydrogel for Knee Osteoarthritis. *Osteoarthritis and Cartilage*, 31(5), P682-683. doi:10.1016/j.joca.2023.02.023.

OUS/ARTHRO/APR2023/064

INTRODUCING ARTHROSAMID®

A new class of injectable therapy to treat knee OA
Safe and sustained pain relief with a single injection¹



Scan here to see our
NEW 3 year data and
latest updates in knee OA



Follow us

- @ConturaLtd
- Contura-Orthopaedics-Ltd
- Contura Orthopaedics Ltd
- @arthrosamid


Ordering information

Contura Orthopaedics Limited, 14 Took's Court, London EC4A 1LB, UK
orders@arthrosamid.com
For full details about warnings and precautions read the IFU. For more information and the IFU please visit www.arthrosamid.com contact us at enquiries@arthrosamid.com.

www.arthrosamid.com
enquiries@arthrosamid.com



iPAAG



Arthrosamid[®] is an injectable polyacrylamide hydrogel (iPAAG) for intra-articular administration that offers patients an effective alternative to current therapies.

A non-biodegradable injectable implant, Arthrosamid[®] delivers long-acting pain relief — improving the quality of life for patients with knee osteoarthritis.¹



BIOCOMPATIBLE

Permeable to salts and organic molecules, the hydrogel is able to integrate with soft tissue.²



VISCOELASTIC

Cross-linked chains of polymer allow flexible shear.²




NON-DEGRADABLE

Structural stability of hydrogel provides longevity of action.²


6ml per treatment session³

Supplied as 6 pre-filled, single use, sterile 1 mL syringes. Injected intra-articularly in the knee joint with a single 21G x 2 inches (0.8 x 50mm) needle.




Electron microscopy images of cryo-frozen and fractured polyacrylamide hydrogel. Magnification x6.000²

A prospective study of polyacrylamide hydrogel (iPAAG) for knee osteoarthritis
Results from 156 weeks after treatment (IDA 3 years)⁹



Statistically significant reduction in pain maintained at 3 years⁹

One-year performance of polyacrylamide hydrogel (iPAAG) vs. hyaluronic acid
Analysis of change from baseline of subgroup <70 years (ROSA)^{2,6}



79% Response rate²

Significant difference in change from baseline between Arthrosamid[®] and Synvisc-One[®] at 52 weeks⁶

iPAAG: Injectable polyacrylamide hydrogel

† WOMAC or The Western Ontario and McMaster Universities Osteoarthritis Index is a measure of symptoms and physical disability LSMeans are modelled/estimated means. The estimated means are using data from the other visits and also the covariates. Synvisc-One is a registered trademark of Sanofi-Aventis U.S. LLC. Arthrosamid is a registered trademark of Contura International A/S. © Copyright 2022 Contura International Ltd

ARTHROSAMID[®]



Simple

A minimally invasive out-patient procedure performed under local anaesthesia, with ultrasound guidance.³



Safe

Arthrosamid[®] is safe for intended use⁶— and has undergone over 20 years of research and development.²



Sustained

In clinical trials, patients reported a reduction in pain by Week 4. This reduction was sustained over 156 weeks.⁹